NEW RESEARCH: 12-page Quarterly Update Available on Pressure BioSciences (PBIO)

This afternoon, we published an update on Pressure BioSciences, Inc. (PBIO-OTC), a company focused on the development and commercialization of proprietary laboratory instruments and consumable products. The update covers the company's most recently reported financial results for the first quarter 2014 and highlights from fiscal year 2013, as well as describes new product introductions, including a new pressure cycling technology (PCT) platform being introduced this week at the annual meeting of the American Society for Mass Spectrometry.

In addition, Pressure BioSciences reached a major milestone in March 2014 with the release of an ultra-high-pressure Barocycler product, the HUB880. This instrument is capable of safe operation up to 100,000 psi, which Pressure BioSciences does not believe is possible with any other bench-top pressure (cycling or constant) products at present. At 100,000 psi, the HUB880 reaches pressures sufficient to kill most pathogenic and food-borne bacteria, and could enable safe investigation of a number of new biological, chemical, material, and industrial sciences applications.

Visit our Corporate Profile page for Pressure BioSciences to read the update and view past research.

13 Things to Know About Pressure BioSciences

• Pressure BioSciences, Inc. is focused on the development and commercialization of proprietary laboratory instruments and consumable products. 

• The Company’s product portfolio is based on its patented pressure cycling technology (PCT), which is able to create and release high levels of hydrostatic pressure in a safe and controlled manner. Pressure BioSciences has 24 issued and 6 pending patents globally that protect various aspects and applications of PCT. 

• The PCT platform is a highly versatile and adaptable technology that can be used across many different industries, including the life sciences, pharmaceutical, biotechnology, forensics, food, anti-bioterror, agriculture, automotive, and oil and gas industries, among others. While Pressure BioSciences believes that its products have potential in each of these markets, the Company is currently focusing its product development efforts on biological sample preparation for life sciences research.

• The sample preparation market for life sciences research is forecast to more than double to $11.5 billion by 2018, driven by new technologies and growing demand.

• Pressure BioSciences’ line of bench-top Barocycler® laboratory instruments employ high pressure to prepare samples for downstream analysis and testing. These PCT-based systems have been shown to extract higher quality and/or quantities of proteins, nucleic acids (DNA/RNA), and small molecules from samples versus competitive products, which could have positive implications in biomarker discovery, forensics, and many other areas of life science research.

• The Company’s customers include large pharmaceutical and biotechnology companies (e.g., Bristol-Myers, Amgen, and Merck), U.S. government agencies (FBI, FDA, NIH, USDA), and universities (Harvard, Stanford, and UCLA). Pressure BioSciences reports that it has installed roughly 250 PCT systems at approximately 150 customer sites as of May 2014.

• Pressure BioSciences’ next-generation PCT platform is the HUB family of Barocyclers. The goal of the HUB is to create a modular system that can grow and adapt to a laboratory’s needs, with users purchasing accessories as needed to expand the functionality of their HUB unit. The newest HUB product, the HUB880 capable of reaching 100,000 psi in a safe and controlled manner, was launched in March 2014.

• Pressure BioSciences has gained exposure to corporate, government, and university laboratories through its strategic collaboration program, which allows third-party researchers to temporarily install a Barocycler instrument in their laboratory in exchange for a reasonable financial commitment and the collection of independent, third-party data on a certain subject.

• Data collected through this program has helped validate existing applications for PCT and establish potential in new applications. As well, much of this research has resulted in peer-reviewed publications and presentations at scientific meetings. To date, over 100 papers have been published on PCT.

• The program also exposes the technology to potential customers as well as specific research scientists who the Company believes could have a positive impact on market acceptance of PCT.

• Pressure BioSciences’ portfolio also includes Shredder instruments (for rapidly shredding or grinding samples), sample preparation kits and reagents, and related consumable products (e.g., sample tubes).

• Pressure BioSciences has multiple novel products in its R&D pipeline, including a high-throughput PCT system scheduled for commercial release during the second quarter 2014 which is designed to meet the needs of larger research and clinical diagnostics laboratories and companies.

• At March 31, 2014, Pressure BioSciences held $428,537 in cash and cash equivalents.